财务数据 - CVS Health在2023年的年度营收为3550亿美元[7] - 调整后的营业收入为174亿美元[7] - 预计2023年全年现金流为300亿美元以上[7] - 健康护理服务的年度营收为1042亿美元[9] - 健康服务的年度营收为1827亿美元[9] - 药房和消费者健康的年度营收为1159亿美元[9] - 预计2023年全年总营收为351.5至357.3亿美元[11] - 预计2023年全年调整后的营业收入为17.21至17.57亿美元[11] - 预计2023年全年调整后的每股收益为8.50至8.70美元[11] - 长期财务指引包括调整后的每股收益增长率不低于6%[12]

公司使命和愿景 - 公司的使命是为每位消费者打造一个健康的世界[4] - 公司致力于提供无缝体验，降低医疗成本，改善整体健康结果[4] 创新和发展 - 公司在创新方面取得了显著进展，推出了新的药房报销模式和新的PBM模式[5] - Cordavis公司计划在未来十年内将生物仿制药市场机会扩大至1000亿美元[43] 业绩和展望 - 公司在2024年预计将提供19亿份处方药[9] - 公司的长期财务指导框架将至少实现6%的每股收益增长[6] - 公司拥有超过1万家药房，服务超过1.2亿客户[11] - 公司计划在2024年至少拥有80万名医疗优势会员[21] - 公司预计2025年将从新的药房报销模式中获得3%至4%的调整后每股收益增长[23] 合作和市场扩张 - Cordavis与AbbVie合作，将HUMIRA从其清单中移除，并与Cordavis联合品牌，以提供更多选择给客户[44] 成本控制和效益 - CostVantage计划旨在稳定药店的报酬模式，提供透明的药品采购成本加上利润率和费用的模式[62] - Aetna计划通过改进服务、关注慢性病患者的用药依从性等措施，提高星级评级，并建立可持续的流程[55] - Aetna已经在价值医疗领域取得了一定成就，通过提供药物依从性等服务，获得了回报[67] - Aetna预计通过改进采购成本，将成本节约传递给客户，以及在2026年和2027年大量药物进入仿制药市场，进一步降低成本[69] - CostVantage产品的定价模式主要针对PBM，而现金支付的消费者可以在第二季度享受到柜台价格优惠[73] - Aetna一直在为客户节省药店成本，并期待FTC报告将继续证明PBM行业的节省成本效果[75] 股东回报和资本部署 - 公司计划继续投资于核心业务，并为股东部署资本，包括提高股息和回购计划[77]

JavaScript被禁用 - 网站上的JavaScript代码被禁用，导致用户无法正常浏览网页内容[1] - 用户无法使用网站上的交互功能，如表单提交、动态加载等[1] - 网站的用户体验受到影响，可能导致用户流失和降低转化率[1]

医疗保健行业表现 - 2023年，医疗保健行业整体表现不佳，除非持有辉瑞（LLY）和诺和诺德（NVO）的股份，否则可能低于标普500指数[1] - 医疗保健选择部门SPDR ETF（XLV）的回报率较低[1] CVS Health前景 - CVS Health（NYSE：CVS）未来有更多上涨空间，公司最近重申了指导意见[2] - CVS Health公司估值被认为被低估，技术面也变得更加有利[2] CVS Health公司介绍 - CVS Health Corporation是美国提供医疗服务的公司，通过医疗保健福利、药房服务和零售/长期护理部门运营[4] - CVS Health是美国最大的医疗保健公司之一，提供零售、邮购和专业药房服务以及药房福利[4]

任命新高管 - 汤姆·考伍伊被任命为首席财务官[2] - 迈克·皮科斯被任命为医疗服务交付总裁[2] 高管背景 - 汤姆的经验丰富，曾在Aetna担任不同战略和财务职位[4] - 迈克在Oak Street Health担任CEO，帮助统一CVS Health的医疗服务资产[5] 肯定新高管 - 公司肯定汤姆和迈克的能力，认为他们能够继续推动公司的战略和承诺[3] 公司支持 - 公司对肖恩的决定给予全力支持，感谢他在团队中的贡献[6] 公司概况 - CVS Health是领先的健康解决方案公司，通过本地渠道、数字渠道和超过30万名员工提供服务[7]

In the latest market close, CVS Health (CVS) reached $80.51, with a -0.46% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.34%. Elsewhere, the Dow saw an upswing of 0.03%, while the tech-heavy Nasdaq depreciated by 0.56%.Shares of the drugstore chain and pharmacy benefits manager have appreciated by 10.04% over the course of the past month, outperforming the Retail-Wholesale sector's gain of 3.02% and the S&P 500's gain of 2.56%.The investment communi ...

CVS Pharmacy, the retail division of CVS Health, simplified its loyalty program by consolidating it into one membership with two tiers.With both tiers of the ExtraCare program, CVS Pharmacy will offer in-store savings, online sales and personalized deals that will be emailed or texted to members, the company said in a Thursday (Jan. 4) press release.“ExtraCare is a long-standing leader in the loyalty program industry, and this evolution will allow us to provide even greater simplicity to our members while p ...

ExtraCare® is now one easy savings membership with two tiersWOONSOCKET, R.I., Jan. 4, 2024 /PRNewswire/ -- CVS Pharmacy®, the retail division of CVS Health® (NYSE: CVS), today announced the evolution of its loyalty program to include two membership tiers: ExtraCare® and ExtraCare Plus™. ExtraCare Plus, the CVS Pharmacy loyalty and membership program formerly known as CarePass, unlocks all the benefits of ExtraCare, plus the new convenience of free same-day delivery of nearly all products in the store in ...

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugstore chain and pharmacy benefits manager have returned +10%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Retail - Pharmacies and Drug Stores industry, which CVS Health falls in, has gained 18.8%. The key question now is: What could b ...

ToplineCVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie’s Humira from its list of covered drugs with cheaper alternatives for some customers—a move that’s sure to take a chunk out of eye-popping Humira sales that have generated hundreds of billions for AbbVie.Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. (AP Photo/David J. ... [+] Phillip, File)Associated Press Key FactsCVS said in a statement that Humira will be remove ...